Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women
- 299 Downloads
One-year treatment of osteoporotic postmenopausal women with transdermal estrogen resulted in significant decreases in bone marrow adipocyte volume and prevented increases in adipocyte number as compared to placebo-treated controls. Estrogen treatment also prevented increases in mean adipocyte size over 1 year.
Aging is associated not only with bone loss but also with increases in bone marrow adipocytes. Since osteoblasts and adipocytes are derived from a common precursor, it is possible that with aging, there is a preferential “switch” in commitment of this precursor to the adipocyte over the osteoblast lineage. We tested the hypothesis that the apparent “age-related” increase in marrow adipocytes is due, at least in part, to estrogen (E) deficiency.
Reanalysis of bone biopsies from a randomized, placebo-controlled trial involving 56 postmenopausal osteoporotic women (mean age, 64 years) treated either with placebo (PL, n = 27) or transdermal estradiol (0.1 mg/d, n = 29) for 1 year.
Adipocyte volume/tissue volume (AV/TV) and adipocyte number (Ad#) increased (by ∼20%, P < 0.05) in the PL group, but were unchanged (Ad#) or decreased (AV/TV, by −24%, P < 0.001) in the E group. E treatment also prevented increases in mean adipocyte size over 1 year.
These findings represent the first in vivo demonstration in humans that not only ongoing bone loss, but also the increase in bone marrow adipocyte number and size in postmenopausal osteoporotic women may be due, at least in part, to E deficiency.
KeywordsAdipocytes Bone Osteoporosis
We thank Dr. Jean Sibonga, JSC Bone and Mineral Laboratory, USRA, NASA, Texas, for helpful discussions, Donna Jewison and Julie Burgess in the bone histomorphometry laboratory for help with locating the samples and archived data, and Kelly Hoey for technical assistance.
Conflicts of interest
- 5.Aubin JE, Liu F (1996) The osteoblast lineage. In: Bilezikian J, Raisz L, Rodan G (eds) Principles of bone biology. Academic Press, San Diego, CA., pp 51–68Google Scholar
- 16.Cooke PS, Naaz A (2004) Role of estrogens in adipocyte development and function. Exp Biol Med 229:1127–1135Google Scholar
- 18.Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, Matsumoto T (2002) Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 143:2349–2356PubMedCrossRefGoogle Scholar
- 25.Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B (2004) Estrogen controls by lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab 89:1869–1878PubMedCrossRefGoogle Scholar
- 36.Rickard DJ, F-LW, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta BJ, Stroup GB, Kumar S, Nuttall ME (2006) Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule against of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39:1361–1372PubMedCrossRefGoogle Scholar
- 37.Kulkarni N, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N’cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE (in press DOI 10.1002/jcb.21374) Changes in osteoblast, chondrocyte, and adipocytes lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem